Lopressor dosage and administration: Difference between revisions

Jump to navigation Jump to search
GeraldChi (talk | contribs)
No edit summary
GeraldChi (talk | contribs)
 
(4 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Metoprolol tartrate#Adult Indications and Dosage]]
{{Metoprolol}}
{{CMG}}
 
===Hypertension===
 
Individualize the dosage of Lopressor [[tablet]]s. Lopressor [[tablet]]s should be taken with or immediately following meals.
 
The usual initial dosage of Lopressor [[tablet]]s is 100 mg daily in single or divided doses, whether used alone or added to a [[diuretic]]. Increase the dosage at weekly (or longer) intervals until optimum [[blood pressure]] reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after 1 week of therapy. The effective dosage range of Lopressor [[tablet]]s is 100-450 mg per day. Dosages above 450 mg per day have not been studied. While once-daily dosing is effective and can maintain a reduction in [[blood pressure]] throughout the day, lower doses (especially 100 mg) may not maintain a full effect at the end of the 24-hour period, and larger or more frequent daily doses may be required. This can be evaluated by measuring [[blood pressure]] near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the day. [[Beta1]] selectivity diminishes as the dose of Lopressor is increased.
 
===Angina Pectoris===
 
The dosage of Lopressor [[tablet]]s should be individualized. Lopressor [[tablet]]s should be taken with or immediately following meals.
 
The usual initial dosage of Lopressor [[tablet]]s is 100 mg daily, given in two divided doses. gradually increase the dosage at weekly intervals until optimum clinical response has been obtained or there is pronounced slowing of the [[heart rate]]. The effective dosage range of Lopressor [[tablet]]s is 100-400 mg per day. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of 1-2 weeks ''(see [[Lopressor warnings and precautions|WARNINGS]])''.
 
===Myocardial Infarction===
 
'''Early Treatment''': During the early phase of definite or suspected [[acute myocardial infarction]], initiate treatment with Lopressor as soon as possible after the patient’s arrival in the hospital. Such treatment should be initiated in a [[coronary care unit|coronary care]] or similar unit immediately after the patient’s [[hemodynamics|hemodynamic condition]] has stabilized.
 
Begin treatment in this early phase with the [[intravenous]] administration of three bolus [[injection]]s of 5 mg of Lopressor each; give the [[injection]]s at approximately 2-minute intervals. During the [[intravenous]] administration of Lopressor, monitor [[blood pressure]], [[heart rate]], and [[electrocardiogram]].
 
In patients who tolerate the full [[intravenous]] dose (15 mg), initiate Lopressor [[tablet]]s, 50 mg every 6 hours, 15 minutes after the last [[intravenous]] dose and continue for 48 hours. Thereafter, the maintenance dosage is 100 mg twice daily ''(see Late Treatment below)''.
 
Start patients who appear not to tolerate the full [[intravenous]] dose on Lopressor [[tablet]]s either 25 mg or 50 mg every 6 hours (depending on the degree of intolerance) 15 minutes after the last [[intravenous]] dose or as soon as their clinical condition allows. In patients with severe intolerance, discontinue Lopressor ''(see [[Lopressor warnings and precautions|Warnings]])''.
 
'''Late Treatment''': Start patients with contraindications to treatment during the early phase of suspected or definite [[myocardial infarction]], patients who appear not to tolerate the full early treatment, and patients in whom the physician wishes to delay therapy for any other reason on Lopressor [[tablet]]s, 100 mg twice daily, as soon as their clinical condition allows. Continue therapy for at least 3 months. Although the efficacy of Lopressor beyond 3 months has not been conclusively established, data from studies with other [[beta blocker]]s suggest that treatment should be continued for 1-3 years.
 
===Special populations===
 
'''Pediatric patients''': No pediatric studies have been performed. The safety and efficacy of Lopressor in [[pediatric]] patients have not been established.
 
'''Renal impairment''': No dose adjustment of Lopressor is required in patients with [[renal impairment]].
 
'''Hepatic impairment''': Lopressor blood levels are likely to increase substantially in patients with [[hepatic impairment]]. Therefore, Lopressor should be initiated at low doses with cautious gradual dose titration according to clinical response.
 
'''Geriatric patients (>65 years)''': In general, use a low initial starting dose in elderly patients given their greater frequency of decreased [[hepatic]], [[renal]], or [[cardiac]] function, and of concomitant disease or other drug therapy.
 
===Method of administration===
 
'''Parenteral administration''' of Lopressor (ampoule) should be done in a setting with intensive monitoring.
 
''Note: [[Parenteral]] drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.''
 
'''For oral treatment''', the [[tablet]]s should be swallowed un-chewed with a glass of water. Lopressor should always be taken in standardized relation with meals. If the physician asks the patient to take Lopressor either before breakfast or with breakfast, then the patient should continue taking Lopressor with the same schedule during the course of therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LOPRESSOR (METOPROLOL TARTRATE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb05420c-fd24-4672-9f62-fdd313819287 | publisher =  | date =  | accessdate = }}</ref>
 
==References==
 
{{Reflist}}
 
{{FDA}}
 
[[Category:Antianginals]]
[[Category:Antiarrhythmic agents]]
[[Category:Antihypertensive agents]]
[[Category:Antimigraine drugs]]
[[Category:Beta blockers]]
[[Category:Cardiovascular Drugs]]

Latest revision as of 03:46, 22 July 2014